drugset
drugset / Trial / NCT04511702

Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

NCT04511702 ↗

Phase 4 Completed 191 enrolled Amgen
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.

Timeline

Start
2020-10-02
Primary completion
2024-01-18
Completion
2024-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegloticase Protein / enzyme biologic 8 mg —
Background MTX Unknown 15 mg Oral

Indications

gout